• Je něco špatně v tomto záznamu ?

COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes

B. Bigdelou, MR. Sepand, S. Najafikhoshnoo, JAT. Negrete, M. Sharaf, JQ. Ho, I. Sullivan, P. Chauhan, M. Etter, T. Shekarian, O. Liang, G. Hutter, R. Esfandiarpour, S. Zanganeh

. 2022 ; 13 (-) : 890517. [pub] 20220527

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018304

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated symptoms, named coronavirus disease 2019 (COVID-19), have rapidly spread worldwide, resulting in the declaration of a pandemic. When several countries began enacting quarantine and lockdown policies, the pandemic as it is now known truly began. While most patients have minimal symptoms, approximately 20% of verified subjects are suffering from serious medical consequences. Co-existing diseases, such as cardiovascular disease, cancer, diabetes, and others, have been shown to make patients more vulnerable to severe outcomes from COVID-19 by modulating host-viral interactions and immune responses, causing severe infection and mortality. In this review, we outline the putative signaling pathways at the interface of COVID-19 and several diseases, emphasizing the clinical and molecular implications of concurring diseases in COVID-19 clinical outcomes. As evidence is limited on co-existing diseases and COVID-19, most findings are preliminary, and further research is required for optimal management of patients with comorbidities.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018304
003      
CZ-PrNML
005      
20220804134704.0
007      
ta
008      
220720s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2022.890517 $2 doi
035    __
$a (PubMed)35711466
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bigdelou, Banafsheh $u Department of Bioengineering, University of Massachusetts Dartmouth, Dartmouth, MA, United States
245    10
$a COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes / $c B. Bigdelou, MR. Sepand, S. Najafikhoshnoo, JAT. Negrete, M. Sharaf, JQ. Ho, I. Sullivan, P. Chauhan, M. Etter, T. Shekarian, O. Liang, G. Hutter, R. Esfandiarpour, S. Zanganeh
520    9_
$a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated symptoms, named coronavirus disease 2019 (COVID-19), have rapidly spread worldwide, resulting in the declaration of a pandemic. When several countries began enacting quarantine and lockdown policies, the pandemic as it is now known truly began. While most patients have minimal symptoms, approximately 20% of verified subjects are suffering from serious medical consequences. Co-existing diseases, such as cardiovascular disease, cancer, diabetes, and others, have been shown to make patients more vulnerable to severe outcomes from COVID-19 by modulating host-viral interactions and immune responses, causing severe infection and mortality. In this review, we outline the putative signaling pathways at the interface of COVID-19 and several diseases, emphasizing the clinical and molecular implications of concurring diseases in COVID-19 clinical outcomes. As evidence is limited on co-existing diseases and COVID-19, most findings are preliminary, and further research is required for optimal management of patients with comorbidities.
650    12
$a COVID-19 $x epidemiologie $7 D000086382
650    _2
$a kontrola infekčních nemocí $7 D003140
650    _2
$a lidé $7 D006801
650    _2
$a pandemie $7 D058873
650    _2
$a karanténa $7 D011790
650    _2
$a SARS-CoV-2 $7 D000086402
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Sepand, Mohammad Reza $u Department of Bioengineering, University of Massachusetts Dartmouth, Dartmouth, MA, United States
700    1_
$a Najafikhoshnoo, Sahar $u Department of Electrical Engineering, University of California, Irvine, CA, United States $u Department of Biomedical Engineering, University of California, Irvine, Irvine, CA, United States $u Laboratory for Integrated Nano Bio Electronics Innovation, The Henry Samueli School of Engineering, University of California, Irvine, Irvine, CA, United States
700    1_
$a Negrete, Jorge Alfonso Tavares $u Department of Electrical Engineering, University of California, Irvine, CA, United States $u Department of Biomedical Engineering, University of California, Irvine, Irvine, CA, United States $u Laboratory for Integrated Nano Bio Electronics Innovation, The Henry Samueli School of Engineering, University of California, Irvine, Irvine, CA, United States
700    1_
$a Sharaf, Mohammed $u Department of Chemical and Biomolecular Engineering, New York University, New York, NY, United States
700    1_
$a Ho, Jim Q $u Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, United States
700    1_
$a Sullivan, Ian $u Department of Bioengineering, University of Massachusetts Dartmouth, Dartmouth, MA, United States
700    1_
$a Chauhan, Prashant $u Institute of Parasitology, Biology Centre Czech Academy of Science, Ceske Budejovice, Czech Republic
700    1_
$a Etter, Manina $u Department of Neurosurgery, University Hospital Basel, Basel, Switzerland
700    1_
$a Shekarian, Tala $u Department of Neurosurgery, University Hospital Basel, Basel, Switzerland
700    1_
$a Liang, Olin $u Division of Hematology/Oncology, Department of Medicine, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, RI, United States
700    1_
$a Hutter, Gregor $u Department of Neurosurgery, University Hospital Basel, Basel, Switzerland
700    1_
$a Esfandiarpour, Rahim $u Department of Electrical Engineering, University of California, Irvine, CA, United States $u Department of Biomedical Engineering, University of California, Irvine, Irvine, CA, United States $u Laboratory for Integrated Nano Bio Electronics Innovation, The Henry Samueli School of Engineering, University of California, Irvine, Irvine, CA, United States
700    1_
$a Zanganeh, Steven $u Department of Bioengineering, University of Massachusetts Dartmouth, Dartmouth, MA, United States
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 13, č. - (2022), s. 890517
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35711466 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134658 $b ABA008
999    __
$a ok $b bmc $g 1822077 $s 1169547
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 13 $c - $d 890517 $e 20220527 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace